Literature DB >> 29214441

Use of 111In-pentetreotide scintigraphy for diagnosis and management of resistant macroprolactinoma.

V Del Gatto1, C Bima1, S Chiloiro2, A Giampietro1, A Bianchi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29214441     DOI： 10.1007/s12020-017-1486-z

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  2 in total

1.  Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma.

Authors:  Alessandra Fusco; Francesca Lugli; Eugenia Sacco; Laura Tilaro; Antonio Bianchi; Flavia Angelini; Anna Tofani; Angela Barini; Libero Lauriola; Giulio Maira; Alfredo Pontecorvi; Laura de Marinis
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

Review 2.  Future treatment strategies of aggressive pituitary tumors.

Authors:  Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2009       Impact factor: 4.107
  2 in total
  2 in total

1.  Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.

Authors:  Renato Cozzi; Maria Rosaria Ambrosio; Roberto Attanasio; Claudia Battista; Alessandro Bozzao; Marco Caputo; Enrica Ciccarelli; Laura De Marinis; Ernesto De Menis; Marco Faustini Fustini; Franco Grimaldi; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Marco Losa; Pietro Maffei; Davide Milani; Maurizio Poggi; Michele Zini; Laurence Katznelson; Anton Luger; Catalina Poiana
Journal:  Eur J Endocrinol       Date:  2022-02-03       Impact factor: 6.664

2.  Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study.

Authors:  Chiara Bima; Sabrina Chiloiro; Antonella Giampietro; Marco Gessi; Pier Paolo Mattogno; Liverana Lauretti; Carmelo Anile; Guido Rindi; Alfredo Pontecorvi; Laura De Marinis; Antonio Bianchi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-12       Impact factor: 5.555
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.